NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$4.65

+0.45 (+10.71 %)

(As of 09/17/2021 04:00 PM ET)

Add

Compare

Today's Range

$4.25

▼

$4.66

50-Day Range

$3.55

▼

$4.72

52-Week Range

$3.30

▼

$8.15

Volume139,137 shs

Average Volume284,843 shs

Market Capitalization$58.17 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.68

30 days | 90 days | 365 days | Advanced Chart

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

About Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Neovasc shares jump 15% on FDA approval of COSIRA-II Reducer trial - Seeking Alpha
September 17, 2021 | seekingalpha.com

Corvus Pharmaceuticals, Innate Pharma lead healthcare gainers; Protagonist Therapeutics, TCR2 Therapeutics among major losers - Seeking Alpha
September 17, 2021 | seekingalpha.com

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022 - Seeking Alpha
September 15, 2021 | seekingalpha.com

Biomerica, Inc. (NASDAQ:BMRA) Expected to Post Earnings of -$0.12 Per Share
September 12, 2021 | americanbankingnews.com

FY2022 EPS Estimates for Biomerica, Inc. Reduced by Analyst (NASDAQ:BMRA)
September 3, 2021 | americanbankingnews.com

FY2022 EPS Estimates for Biomerica, Inc. Decreased by Analyst (NASDAQ:BMRA)
September 1, 2021 | americanbankingnews.com

Biomerica, Inc. (NASDAQ:BMRA) Expected to Post Q1 2022 Earnings of ($0.12) Per Share
August 31, 2021 | americanbankingnews.com

Biomerica Says Expects Completion Of Patient Enrollment For InFoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week - Benzinga
August 30, 2021 | benzinga.com

Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical - GlobeNewswire
August 30, 2021 | globenewswire.com

Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
Previous Symbol
CUSIPN/A
CIK73290
Webwww.biomerica.com
Phone(949) 645-2111
Employees45
Year FoundedN/A

Sales & Book Value

Annual Sales$7.20 million
Price / Sales8.08
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.75 per share
Price / Book6.20

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-6,470,000.00
Net Margins-89.83%
Return on Equity-59.47%
Return on Assets-46.58%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares12,510,000
Market Cap$58.17 million
Next Earnings Date10/21/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.94 out of 5 stars

Medical Sector

625th out of 1,351 stocks

Diagnostic Substances Industry

8th out of 25 stocks

3.5 Analyst's Opinion

Consensus Rating
Biomerica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.33, Biomerica has a forecasted upside of 143.7% from its current price of $4.65.
Amount of Analyst Coverage
Biomerica has only been the subject of 1 research reports in the past 90 days.

4.5 Community Rank

Outperform Votes
Biomerica has received 134 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biomerica has received 65 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biomerica has received 67.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote “Outperform” if you believe BMRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biomerica does not currently pay a dividend.
Dividend Growth
Biomerica does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biomerica insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.70% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.85% of the stock of Biomerica is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Biomerica is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biomerica is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biomerica has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

Is Biomerica a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biomerica stock.
View analyst ratings for Biomerica or view top-rated stocks.

What stocks does MarketBeat like better than Biomerica?

Wall Street analysts have given Biomerica a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biomerica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biomerica?

Biomerica saw a increase in short interest in the month of July. As of July 30th, there was short interest totaling 1,120,000 shares, an increase of 13.5% from the July 15th total of 986,900 shares. Based on an average trading volume of 321,000 shares, the short-interest ratio is presently 3.5 days. Approximately 11.0% of the company's stock are short sold.
View Biomerica's Short Interest.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Thursday, October 21st 2021.
View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its earnings results on Thursday, April, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07. Biomerica had a negative trailing twelve-month return on equity of 59.47% and a negative net margin of 89.83%.
View Biomerica's earnings history.

How has Biomerica's stock been impacted by Coronavirus (COVID-19)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 60.3% and is now trading at $4.65.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BMRA?

3 equities research analysts have issued 1 year target prices for Biomerica's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Biomerica's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 143.7% from the stock's current price.
View analysts' price targets for Biomerica or view top-rated stocks among Wall Street analysts.

Who are Biomerica's key executives?

Biomerica's management team includes the following people:

Zackary S. Irani, Chairman & Chief Executive Officer
Steve Sloan, Chief Financial Officer
Allen C. Barbieri, Executive Vice Chairman & Secretary
Joshua S. Horowitz, Board Observer

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), Global WholeHealth Partners (GWHP), StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), Fuse Science (DROP), BG Medicine (BGMD), FluoroPharma Medical (FPMI) and Hemagen Diagnostics (HMGN).
View all of BMRA's competitors.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.72%), M&G Investment Management Ltd. (1.33%), Fore Capital LLC (1.10%), GSA Capital Partners LLP (0.85%), Geode Capital Management LLC (0.60%) and State Street Corp (0.44%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica.

Which institutional investors are selling Biomerica stock?

BMRA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Susquehanna International Group LLP.
View insider buying and selling activity for Biomerica or view top insider-selling stocks.

Which institutional investors are buying Biomerica stock?

BMRA stock was acquired by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., GSA Capital Partners LLP, Fore Capital LLC, State Street Corp, Simplex Trading LLC, GWM Advisors LLC, Orion Capital Management LLC, and XTX Topco Ltd.
View insider buying and selling activity for Biomerica or or view top insider-buying stocks.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $4.65.

How much money does Biomerica make?

Biomerica has a market capitalization of $58.17 million and generates $7.20 million in revenue each year. The company earns $-6,470,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Biomerica have?

Biomerica employs 45 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

Where are Biomerica's headquarters?

Biomerica is headquartered at 17571 Von Karman Avenue, Irvine CA, 92614.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at (949) 645-2111.

This page was last updated on 9/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here